Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients
- PMID: 11169519
- DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH730>3.0.CO;2-2
Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients
Abstract
Galectin-1, a member of the beta-galactoside-binding galectin family, is a pleiotropic dimeric protein participating in a variety of normal and pathological processes, including cancer progression. Modulation of the interactions with the basement membrane glycoprotein laminin and induction of apoptosis in activated T lymphocytes are well-known functions of this galectin. In this study, the expression of galectin-1 was examined in 148 human primary prostate carcinoma samples. Immunohistochemical staining of paraffin sections of prostate tissues revealed that galectin-1 was not detected in normal, PIN (prostatic intraepithelial neoplasia) or carcinoma cells, but accumulated in the stroma and associated fibroblasts. Galectin-1 expression was significantly increased in the tumour-associated stroma compared with the non-neoplastic gland-associated stroma in 21.3% of the cases (Mantel-Haenszel test, p=0.001; Wilcoxon signed rank test, p<0.0001). Increased galectin-1 expression in the cancer-associated stroma compared to the normal gland-associated stroma (p=0.03) was identified by multivariate analysis as a strong independent predictor of prostate-specific antigen (PSA) recurrence, just after the pathological stage (p<0.0001). The association between accumulation of galectin-1 in the stroma of the malignant tissue and aggressiveness of the tumour adds weight to the body of evidence that identifies a role for galectin-1 in the acquisition of the invasive phenotype. In addition to modulating cancer cell interactions with laminin, galectin-1 accumulated around the cancer cells may act as an immunological shield by inducing activated T-cell apoptosis. This exciting hypothesis warrants further investigation.
Similar articles
-
Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.Eur Urol. 2007 May;51(5):1259-66. doi: 10.1016/j.eururo.2006.05.050. Epub 2006 Jun 14. Eur Urol. 2007. PMID: 16806661
-
Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.Cancer. 2003 Mar 1;97(5):1225-33. doi: 10.1002/cncr.11198. Cancer. 2003. PMID: 12599229
-
Heat shock protein expression independently predicts clinical outcome in prostate cancer.Cancer Res. 2000 Dec 15;60(24):7099-105. Cancer Res. 2000. PMID: 11156417
-
Expression of galectin-1 in malignant tumors.Exp Oncol. 2009 Jun;31(2):74-9. Exp Oncol. 2009. PMID: 19550395 Review.
-
Galectin-3: a novel mediator of heart failure development and progression.Eur J Heart Fail. 2009 Sep;11(9):811-7. doi: 10.1093/eurjhf/hfp097. Epub 2009 Jul 31. Eur J Heart Fail. 2009. PMID: 19648160 Review.
Cited by
-
CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.Pathol Oncol Res. 2010 Dec;16(4):569-77. doi: 10.1007/s12253-010-9248-8. Epub 2010 Feb 23. Pathol Oncol Res. 2010. PMID: 20177845
-
Targeting Angiogenesis in Prostate Cancer.Int J Mol Sci. 2019 May 31;20(11):2676. doi: 10.3390/ijms20112676. Int J Mol Sci. 2019. PMID: 31151317 Free PMC article. Review.
-
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Oncoimmunology. 2015 Apr 1;4(7):e1016700. doi: 10.1080/2162402X.2015.1016700. eCollection 2015 Jul. Oncoimmunology. 2015. PMID: 26140242 Free PMC article. Review.
-
The clinical implication of tumoral Gal-1 expression in laryngeal squamous cell carcinomas.Clin Transl Oncol. 2013 Aug;15(8):608-18. doi: 10.1007/s12094-012-0975-z. Epub 2013 Jan 29. Clin Transl Oncol. 2013. PMID: 23359172
-
Expression of galectins in cancer: a critical review.Glycoconj J. 2002;19(7-9):537-42. doi: 10.1023/B:GLYC.0000014083.48508.6a. Glycoconj J. 2002. PMID: 14758077 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous